Ophthalmology within 24 to 72 hours if any ocular concern
Temporal artery biopsy arrangement
Within 2 weeks of starting steroids
Steroids do not need to be delayed for biopsy
Biopsy remains interpretable up to 2 weeks after initiation
Specialist consultation timing
Referral urgency
Ophthalmology same day for visual symptoms
Any visual loss or amaurosis fugax
Diplopia or ocular motility deficit
Rheumatology within 1 to 2 weeks for all suspected GCA
Biopsy coordination
Steroid taper planning
Vascular surgery if aortic pathology identified
Aneurysm surveillance planning
Acute dissection urgent surgical review
Treatment
Glucocorticoid therapy
Initial steroid dosing
Uncomplicated cranial GCA without vision loss
Prednisone 40 to 60 mg per day orally
Class I recommendation per ACR 2021 guidelines
Vision loss or imminent vision-threatening disease
IV methylprednisolone 1 g per day for 3 days
Transition to oral prednisone 1 mg/kg/day after pulse
Continue until symptoms resolve and inflammatory markers normalize
Typically 2 to 4 weeks at initial dose
ESR and CRP guide response assessment
Steroid taper protocol
Initial taper
Reduce by 10 to 20% per month while monitoring ESR and CRP
Taper more slowly when dose below 20 mg per day
When dose below 10 mg per day
Reduce by 1 mg per month
Accelerate taper if tocilizumab added
Total treatment duration 1 to 5 years
Aim for 0 to 5 mg per day by 12 months when possible
Relapse requires dose increase to prior effective dose
Glucocorticoid-sparing agents
Tocilizumab (IL-6 receptor inhibitor)
Subcutaneous tocilizumab 162 mg weekly
FDA-approved for GCA
Conditionally recommended with glucocorticoids as initial therapy per ACR 2021
Alternative dosing 162 mg every other week
For new diagnosis or lower-risk features
Discuss with rheumatology
Intravenous tocilizumab 8 mg/kg every 4 weeks
Alternative route for selected patients
Maximum dose 800 mg per infusion
Monitoring on tocilizumab
CRP unreliable for disease activity monitoring on therapy
Lipid panel, LFTs, CBC monitoring
Contraindications and precautions
Active infection or high infection risk
Diverticulosis or diverticulitis history
GI perforation risk
Upadacitinib (JAK inhibitor)
Upadacitinib 15 mg orally daily
Recently FDA-approved for GCA
Glucocorticoid-sparing option
Monitoring
Infection surveillance including reactivation of latent TB and herpes zoster
Cardiovascular and thromboembolic risk assessment
Preferred over tocilizumab when
Subcutaneous injection not feasible
Diverticular disease present
Methotrexate (alternative)
Methotrexate 7.5 to 15 mg orally once weekly
Alternative steroid-sparing agent if tocilizumab or upadacitinib contraindicated
Folic acid 1 mg daily to reduce toxicity
Monitoring
CBC and LFTs every 4 to 8 weeks
Renal function monitoring
Avoid in significant hepatic or renal impairment
Agents to avoid
Infliximab should NOT be used in GCA
Associated with worse outcomes in controlled trials
Class III harm designation
Supportive and preventive measures
Steroid-associated complication prevention
Proton pump inhibitor for GI prophylaxis
Omeprazole 20 mg daily or equivalent
Continue while on high-dose steroids
Calcium and vitamin D supplementation
Calcium 1000 to 1500 mg per day
Vitamin D 800 to 1000 IU per day
Bone density monitoring
DEXA scan at baseline
Bisphosphonate consideration per osteoporosis risk
Glucose monitoring
Fasting glucose or HbA1c at baseline
Home glucose monitoring if elevated
Aspirin therapy consideration
Low-dose aspirin 81 mg daily
Consider for ischemic risk reduction in high-risk features
Evidence limited but used in clinical practice for patients with prior ischemic events
Weigh GI bleeding risk
Pneumocystis jirovecii prophylaxis
Trimethoprim-sulfamethoxazole 80/400 mg daily or 160/800 mg three times per week
Consider with prolonged high-dose prednisone above 20 mg per day
Continued for duration of high-dose steroid exposure
Special Populations
Pregnancy
Pregnancy considerations
GCA extremely rare in reproductive age
Age requirement of 50 years virtually excludes pregnancy overlap
Consider other vasculitides if young patient
If GCA occurs in perimenopause
Prednisone preferred initial therapy
Avoid methotrexate in pregnancy
Teratogenic
Contraindicated
Tocilizumab in pregnancy
Limited safety data
Crosses placenta in third trimester
Avoid unless benefit clearly outweighs risk
Steroid effects in pregnancy
Gestational diabetes risk increased
Preeclampsia risk
Fetal monitoring when viable gestation
Geriatric
Geriatric-specific features
GCA is predominantly a disease of older adults
Peak incidence 70 to 75 years
Steroid side effects more severe in this population
Steroid complications magnified
Osteoporosis fracture risk markedly elevated
Delirium and neuropsychiatric effects
Glucose intolerance and diabetes
High rates of steroid-induced hyperglycemia
Insulin management often required
Falls risk on steroids
Proximal muscle weakness from steroids
Physical therapy referral consideration
Modified monitoring in older adults
More frequent bone health assessment
DEXA within 6 months of starting steroids
Bisphosphonate initiation thresholds lower
Renal function monitoring for drug dosing
Age-related decline in GFR
Methotrexate dosing adjustment required
Tocilizumab preferred steroid-sparing approach
Avoids methotrexate toxicity risk
Closely monitor for infections in older adults
Pediatrics
GCA in pediatric patients
Temporal arteritis in patients under 50 is extremely rare
Consider Takayasu arteritis in patients under 40
Consider ANCA-associated vasculitis
Pediatric giant cell arteritis
Distinct from adult GCA
Typically involves intracranial arteries
Treatment if confirmed
High-dose steroids weight-based
Prednisone 1 to 2 mg/kg/day up to 60 mg
Rheumatology-led management mandatory
Tocilizumab in pediatric systemic JIA off-label precedent
Weight-based dosing for pediatric indications
Pediatric rheumatology required
Background
Epidemiology
Incidence and prevalence
Most common primary vasculitis in adults
Incidence 10 to 30 per 100,000 persons age 50 or older per year
Higher rates in Scandinavian populations
Northern European descent highest risk
Swedish and Norwegian populations most affected
Lower rates in Asian and African populations
Female predominance
Women to men ratio approximately 2:1
Hormonal factors suspected but unproven
Risk of complications
Vision loss in 15 to 20% of untreated or undertreated patients
Arteritic AION most common cause of permanent vision loss
Bilateral vision loss possible within days without treatment
Stroke in approximately 7% of confirmed GCA cases
Vertebrobasilar distribution most common
Associated with significantly worse prognosis
Aortic aneurysm risk 17 times higher than age-matched controls
Long-term surveillance required
Often asymptomatic until complication
Relapse epidemiology
Approximately 50% of patients experience at least one relapse
Most common during steroid taper
Minor relapses PMR symptoms in approximately 75%
Major relapses ischemic symptoms in approximately 25%
Pathophysiology
Immunologic mechanisms
Immune-mediated granulomatous vasculitis
CD4+ T-helper cell activation in vessel wall
Macrophage and giant cell recruitment
IL-6 and IL-17 pathways central to inflammation
Rationale for tocilizumab (IL-6 receptor blockade)
JAK-STAT signaling pathway targeted by upadacitinib
HLA-DRB1 04 alleles associated with GCA susceptibility
Genetic predisposition identified
Northern European genetic background
Vessel involvement pattern
Medium and large vessel tropism
Temporal arteries classic involvement
Ophthalmic artery and posterior ciliary artery vision supply
Large-vessel GCA subtype
Aorta, subclavian, axillary arteries
Clinically distinct but may overlap with cranial GCA
Ischemic complications mechanism
Intimal hyperplasia causes luminal occlusion
Internal elastic lamina disruption
Platelet aggregation at inflamed vessel wall
Triggering factors
Infectious triggers suspected
Mycoplasma and Chlamydia pneumoniae implicated but unproven
Varicella-zoster virus arterial tropism studied
Age-related immune senescence
Dendritic cell dysregulation in vessel adventitia
Reduced regulatory T-cell function
Therapeutic Considerations
Steroid dependency and taper
High-dose steroids required initially for ischemic protection
Inflammatory cascade suppression within 24 to 72 hours
Symptom response guides taper pace
Long taper required due to relapse risk
Average treatment duration 2 to 3 years
Taper guided by ESR and CRP when not on tocilizumab
Tocilizumab allows faster steroid taper in GiACTA trial
56% sustained remission at 52 weeks versus 14 to 18% placebo
Steroid cumulative dose substantially reduced
Monitoring strategy
Inflammatory markers guide activity assessment when not on IL-6 inhibitor
ESR and CRP monthly initially then quarterly
Rising markers with symptoms signal relapse
Imaging for large-vessel surveillance
CT or MRI of chest and abdomen every 1 to 2 years
Even after disease remission for aortic aneurysm detection
Ophthalmology monitoring
Baseline and periodic visual field testing
Any new visual symptoms warrant urgent assessment
Treatment failure and refractory disease
True refractory GCA uncommon
Reassess diagnosis if no response to steroids within 72 hours
Alternative diagnoses must be considered
Biologic switch if tocilizumab fails
Upadacitinib as alternative mechanism
Rituximab off-label in selected refractory cases
Infliximab contraindicated based on evidence
Associated with worse outcomes in GCA trials
Class III harm per rheumatology guidelines
Patient Discharge Instructions
copy discharge instructions
Giant cell arteritis (GCA) home care instructions
Take prednisone exactly as prescribed every morning with food
Do not stop or reduce the dose without talking to your doctor first
Stopping suddenly can be dangerous
Take your stomach protection medication (proton pump inhibitor) daily
Take calcium and vitamin D supplements as prescribed
Check blood sugar as instructed if you have diabetes or your doctor recommends it
Warning signs that require immediate return to the emergency department
Any change in vision in either eye
Blurring, darkening, loss of part or all of vision
Double vision
New or worsening headache that is severe
Especially if different from your usual headache
Any sudden severe headache
Pain in the jaw when chewing
Or difficulty opening the mouth fully
Stop eating and seek care immediately
Weakness or numbness in face, arm, or leg
Difficulty speaking or understanding speech
These may be signs of stroke
Chest pain, back pain, or arm pain with activity
May indicate blood vessel involvement in chest
Seek emergency care immediately
Scalp pain or tenderness that suddenly worsens
Especially with any skin color change
Follow-up appointments
Rheumatology within 1 to 2 weeks
They will arrange a biopsy of the temporal artery if needed
They will supervise your steroid taper
Ophthalmology within 24 to 72 hours if you had any eye symptoms
Eye doctor will check your vision carefully
Let your eye doctor know you are being treated for GCA
Blood tests in 1 to 2 weeks
ESR and CRP to check inflammation levels
Blood sugar and other tests as your doctor orders
Steroid side effects to expect and manage
Increased appetite and weight gain
Try to avoid extra salty or sugary foods
Gentle exercise as tolerated
Trouble sleeping
Take prednisone in the morning if possible
Good sleep hygiene
Mood changes or difficulty concentrating
Common with high-dose steroids
Contact your doctor if severe
Increased blood sugar
Monitor blood sugar if diabetic or borderline diabetic
Contact your doctor if readings consistently high
References
Guidelines and key sources
Primary guideline references
2021 ACR/Vasculitis Foundation Guideline for Management of Giant Cell Arteritis and Takayasu Arteritis
Maz M et al. Arthritis Care and Research 2021
Tocilizumab conditional recommendation for initial therapy with glucocorticoids
2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis
Ponte C et al. Arthritis and Rheumatology 2022
Weighted criteria system with imaging incorporated
Landmark trials and systematic reviews
GiACTA Trial tocilizumab in GCA
New England Journal of Medicine 2017
56% sustained remission with weekly subcutaneous tocilizumab
Cochrane Review halo sign versus biopsy 2024
Pouncey AL et al. Cochrane Database of Systematic Reviews
Sensitivity 77%, specificity 96% for temporal artery ultrasound halo sign
Diagnostic accuracy systematic review
van der Geest KSM et al. JAMA Internal Medicine 2020
Likelihood ratios for symptoms, signs, and laboratory tests
Population-based inflammatory marker performance
Castillejo Becerra CM et al. American Journal of Ophthalmology 2025
Both ESR and CRP normal in 3 to 4% of biopsy-proven GCA
Key review articles
Large-Vessel Vasculitis. Lancet 2025
Cacoub P et al.
Comprehensive review including upadacitinib approval
Giant Cell Arteritis. Annals of Internal Medicine 2026
Kermani TA
Current evidence summary with relapse data
High Risk and Low Prevalence Diseases: Giant Cell Arteritis. American Journal of Emergency Medicine 2022
Lacy A, Nelson R, Koyfman A, Long B
Emergency medicine perspective
Coding and classification
ICD-10 M31.5 Giant cell arteritis with polymyalgia rheumatica
ICD-10 M31.6 Other giant cell arteritis
SNOMED CT 400054005 Giant cell arteritis
Temporal arteritis concept included
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.